FIGNL1

Across TCGA pan-cancer cohorts, FIGNL1 mass-spec protein is linked to patient survival in 3 of 34 cancer types, making it a survival-associated FIGNL1 data layer compared with 26 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher FIGNL1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated FIGNL1 expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

LUAD, PDAC, and LSCC are the cancer types where FIGNL1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Quartile	All	0.847	1.000	.032	4	view →
PDAC	OS	Tertile	All	0.772	0.364	.038	4	view →
LSCC	OS	Tertile	All	0.924	0.718	.041	1	view →

Pink = unfavorable, green = favorable. Showing the 3 strongest of 3 lineages.

FIGNL1–LUAD (OS)

Open the LUAD breakdown →